Who
Karimah Es Sabar
Director
Company insider
Files Form 4 as: Director, Capricor Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $7.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 23 Jul 2021
- Last trade
- 2 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K7,529 at $3.18 | filing |
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $241K7,529 at $32.00 | filing |
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,529 at $0.00 | filing |
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,529 at $0.00 | filing |
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K7,529 at $3.18 | filing |
| 2 Apr 2026filed 3 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $241K7,529 at $32.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $261K53,735 at $4.86 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —53,735 at $0.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M53,735 at $31.03 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —53,735 at $0.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $261K53,735 at $4.86 | filing |
| 1 Apr 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M53,735 at $31.03 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $298K61,265 at $4.86 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M61,265 at $30.17 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,265 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,265 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Code M | $298K61,265 at $4.86 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CAPR Capricor TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M61,265 at $30.17 | filing |
| 5 Jan 2026filed 7 Jan 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | CAPR Capricor Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
News
Karimah Es Sabar Joins Linearis Ventures as Strategic Life Sciences and Venture Capital Advisornewswire.ca · 9 Sep 2026
1 headline in the last 90 days name Karimah Es Sabar; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.